10-K: Revvity Reports Modest Revenue Growth Amid Margin Pressures

Revvity, Inc. reported a 4% revenue increase in fiscal year 2025, driven by Diagnostics and Software, but faced declines in net income and gross margins due to tariffs and restructuring costs.

Summary

• Total revenue for fiscal year 2025 increased by 4% to $2,856.1 million, up from $2,755.0 million in fiscal year 2024.
• Life Sciences segment revenue grew by 2% to $1,431.1 million, primarily due to a $35.6 million increase in Software revenue, partially offset by a $3.1 million decrease in Life Sciences Solutions revenue.
• Diagnostics segment revenue increased by 5% to $1,424.9 million, driven by a $41.3 million rise in Immunodiagnostics revenue and a $27.2 million increase in Reproductive Health revenue.
• Consolidated gross margin decreased by 104 basis points to 54.8% in fiscal year 2025, down from 55.8% in fiscal year 2024, mainly due to increased tariffs, unfavorable foreign exchange rates, and product mix shift.
• Net income for fiscal year 2025 was $241.2 million, a decrease from $270.4 million in fiscal year 2024.
• Diluted earnings per share (EPS) decreased to $2.07 in fiscal year 2025 from $2.20 in fiscal year 2024.
• Research and Development (R&D) expenses increased by 10% to $215.8 million, reflecting investments in new product development and unfavorable foreign exchange rates.
• The company repurchased $820.8 million of common stock in fiscal year 2025, significantly higher than $369.6 million in fiscal year 2024.
• A new $1.0 billion stock repurchase program was authorized on October 23, 2025, with $879.5 million remaining available as of December 28, 2025.
• Cash and cash equivalents decreased to $919.9 million as of December 28, 2025, from $1,163.4 million at December 29, 2024.
• The Life Sciences Solutions reporting unit, with $4.5 billion in goodwill, had a fair value exceeding its carrying value by more than 10% but less than 20% as of November 3, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report. While revenue growth in key segments and strategic investments in R&D and acquisitions are positive, the decline in net income, EPS, and gross/operating margins due to tariffs, FX, and restructuring costs present headwinds. The goodwill valuation for the Life Sciences Solutions segment also warrants close monitoring.

Positives

• Total revenue increased by 4% in fiscal year 2025, demonstrating continued top-line growth.
• The Diagnostics segment showed strong growth of 5%, driven by both Immunodiagnostics and Reproductive Health businesses.
• Software revenue within the Life Sciences segment increased by $35.6 million, indicating successful expansion in digital capabilities.
• The company is actively investing in new product development, with R&D expenses increasing by 10% to $215.8 million.
• A new $1.0 billion stock repurchase program was authorized, signaling confidence in future value and commitment to shareholder returns.
• A new senior unsecured revolving credit facility of $1.5 billion was established, extending borrowing capacity through January 7, 2030.
• The company completed the acquisition of Advanced Chemistry Development Inc. (ACD/Labs) for $72 million cash, expanding its scientific software solutions.

Negatives

• Net income decreased to $241.2 million in fiscal year 2025 from $270.4 million in fiscal year 2024.
• Diluted EPS decreased to $2.07 in fiscal year 2025 from $2.20 in fiscal year 2024.
• Consolidated gross margin decreased by 104 basis points to 54.8% in fiscal year 2025, primarily due to increased tariffs and unfavorable foreign exchange rates.
• Increased tariffs during fiscal year 2025 raised cost of revenue by approximately $25 million, with a net impact of approximately $20 million on gross margin.
• Consolidated operating margin decreased by 10 basis points in fiscal year 2025.
• Restructuring and other costs, net, significantly increased to $55.9 million in fiscal year 2025 from $17.5 million in fiscal year 2024, including charges for workforce reductions affecting approximately 5% of the workforce.
• Cash and cash equivalents decreased by $243.5 million in fiscal year 2025.
• Interest income decreased significantly due to a reduction in marketable securities and short-term investments.
• The Life Sciences Solutions reporting unit's fair value exceeded its carrying value by less than 20%, indicating a narrower margin against potential goodwill impairment.

Risks

• Declines in markets or uncertainties in government/industrial funding could adversely affect business operations and demand for products.
• Global economic and political conditions, including inflation, recession, trade barriers, and conflicts, could disrupt the supply chain and operations.
• Failure to introduce new products in a timely manner or invest in commercially viable technology could lead to market share loss and missed revenue targets.
• Inability to successfully execute acquisitions or divestitures, integrate acquired businesses, or maintain licensed technologies could harm profitability.
• Aggressive competition from numerous competitors, including larger multinational organizations, could impact market share and pricing.
• Significant fluctuations in quarterly operating results due to market conditions, competitive pressures, or changes in economic activity could increase stock price volatility.
• Disruptions in third-party package delivery and import/export services, or price increases, could interfere with product shipments and increase costs.
• Reliance on limited or single sources for critical raw materials and components could lead to supply disruptions and damage customer relationships.
• Failure to retain key personnel, including executive officers and technical staff, or successfully execute leadership succession plans, could limit business strategy execution.
• Significant disruption or breach in information technology systems, or cybercrime, could result in losses, misappropriation of assets, or unauthorized disclosure of confidential information.
• Uncertainties related to the development, deployment, and use of AI, including flawed algorithms, biased datasets, or regulatory changes, could harm business and reputation.
• Failure to realize the full value of intangible assets, particularly goodwill, could result in impairment charges and adversely affect results of operations.
• Exposure to product and other liability claims if products or services cause injury, damage, or loss, potentially exceeding insurance coverage.
• Failure to maintain satisfactory compliance with regulations of the FDA and other governmental agencies could lead to recalls, manufacturing cessation, and civil/criminal penalties.
• Non-compliance with stringent data privacy and information security laws and regulations could result in significant fines and reputational damage.
• Changes in governmental regulations (e.g., environmental, health and safety, data privacy, food and drug) could reduce demand or increase expenses.
• Failure to comply with extensive healthcare industry laws and regulations could lead to fines, penalties, and loss of licenses.
• Economic, political, and other risks associated with foreign operations (e.g., currency exchange rates, global health crises, trade protectionism, differing tax laws) could adversely affect international sales and profitability.
• Substantial outstanding debt could impact future financing ability, limit other expenditures, expose the company to interest rate/foreign currency risk, and increase downgrade chances.
• Restrictive covenants in debt instruments may limit activities such as paying dividends, selling assets, or incurring obligations.

Future Outlook

The company projects an increase in capital expenditures in fiscal year 2026 to enhance digital capabilities, product innovations, and realign production infrastructure, funded by existing cash reserves and internally generated funds. Management anticipates internal operations will generate sufficient cash to fund operating expenses, capital expenditures, acquisitions, interest payments, and dividends for at least the next 12 months. The fiscal year ending January 3, 2027 (fiscal year 2026) will include 53 weeks.

Management Comments

• "Our overall revenue in fiscal year 2025 increased by $101.1 million, or 4%, as compared to fiscal year 2024, reflecting an increase of $68.5 million, or 5%, in Diagnostics segment revenue and an increase of $32.5 million, or 2%, in Life Sciences segment revenue."
• "Overall, we believe that our range of product offerings, leading market positions, global scale and financial strength provides us with a foundation for continued long-term growth, margin expansion and robust cash flow generation."
• "The increase in research and development expenses was primarily driven by unfavorable changes in foreign exchange rates and our investments in new product development."
• "We expect to repay the 2026 Notes with our existing cash on hand or borrowings under our senior unsecured revolving credit facility, or a combination thereof."
• "In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources."

Industry Context

StockSavvy.ai notes that Revvity's focus on health science solutions, particularly in translational multi-omics, biomarker identification, and diagnostics, aligns with broader industry trends emphasizing precision medicine and advanced research tools. The increased R&D investment and strategic acquisition of ACD/Labs reflect a commitment to innovation and digital transformation, crucial for maintaining competitiveness in a rapidly evolving life sciences and diagnostics market. However, the impact of tariffs and foreign exchange fluctuations on gross margins highlights the globalized nature of the industry and the ongoing challenges of international trade and supply chain management.

Comparison to Industry Standards

• The 4% revenue growth is modest compared to some high-growth segments within the broader life sciences tools and services industry, which can see double-digit growth, but is respectable given global economic headwinds.
• The decline in gross margin due to tariffs and product mix shift indicates that Revvity is facing similar supply chain and cost pressures as many global manufacturing and technology companies, though specific comparable company data is not provided in the filing.
• The increase in R&D spending to 7.6% of revenue suggests a commitment to innovation that is generally in line with or slightly above industry averages for established life science technology providers, aiming to stay competitive with peers like Thermo Fisher Scientific or Danaher Corporation in specific product areas.
• The company's strategic focus on AI integration into product offerings and internal operations positions it to leverage a key technological trend, similar to initiatives seen across leading players in the health tech and biotech sectors.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations arising in the ordinary course of business, including product liability claims.
• Accruals for potential losses believed to be probable and reasonably estimable have been established.
• Management does not anticipate the total cost of resolving these contingencies to have a material adverse effect on the consolidated financial statements as of December 28, 2025.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, but potentially benefit from the new $1.0 billion share repurchase program and continued quarterly dividends. Anti-takeover provisions may affect acquisition premiums.
• Employees: Affected by workforce reductions (approximately 5% in FY2025) and facility consolidations as part of restructuring efforts, but also benefit from competitive compensation, development opportunities, and a focus on positive workplace culture.
• Customers: Benefit from increased R&D investments leading to new product development and enhanced digital capabilities, but may experience impacts from supply chain disruptions or pricing adjustments due to tariffs.
• Creditors: The company's debt levels and covenants are managed, with plans to repay the 2026 Notes, which impacts their risk exposure and future financing terms.
• Suppliers: May be affected by manufacturing optimization and supplier collaboration strategies implemented to mitigate tariff impacts.

Next Steps

• Repay the 1.875% Notes due 2026 with existing cash or borrowings under the senior unsecured revolving credit facility by July 19, 2026.
• Continue capital expenditures in fiscal year 2026 to enhance digital capabilities, product innovations, and realign production infrastructure.
• Operate under the new $1.0 billion stock repurchase program, which expires on October 22, 2027.
• Integrate the recently acquired Advanced Chemistry Development Inc. (ACD/Labs) into the Life Sciences segment.

Key Dates

Recommendation

Revvity's fiscal year 2025 results present a mixed picture. While the company achieved modest revenue growth, particularly in its Diagnostics and Software segments, it experienced declines in net income and diluted EPS, alongside a notable decrease in gross and operating margins. These pressures are attributed to increased tariffs, unfavorable foreign exchange rates, and significant restructuring costs, including workforce reductions. However, the company is actively investing in R&D and strategic acquisitions like ACD/Labs, which could drive future growth. The authorization of a new $1.0 billion share repurchase program and the plan to repay the 2026 Notes demonstrate prudent capital management. The goodwill valuation for the Life Sciences Solutions segment, while not impaired, warrants close monitoring. Given the combination of current headwinds impacting profitability and strategic investments aimed at long-term growth, a 'hold' recommendation is appropriate, suggesting investors monitor the effectiveness of these strategic initiatives and the resolution of margin pressures.

Keywords

Health Science, Life Sciences, Diagnostics, Biotechnology, Pharmaceutical, Medical Devices, Software, Immunodiagnostics, Reproductive Health, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Management, Artificial Intelligence, Share Repurchase, Debt Management, Tariffs, Foreign Exchange